MTOR and neoplasm: PI3K/AKT/mTOR inhibitors can not only act on tumor cells but also work on immune cells and TME, which can improve the capacity of tumor immune surveillance, so combining ICIs and PI3K/AKT/mTOR inhibitors may promote the efficacy and reduce the resistance [112].